Novo Nordisk Archives -

Novo Nordisk has reported phase 3 results with its concizumab drug for haemophilia A or B, showing efficacy

Novo Nordisk’s concizumab hits mark in haemophilia, but dosing questioned

https://pharmaphorum.com/news/novo-nordisks-concizumab-hits-mark-in-haemophilia-but-dosing-questioned/

News/ News/ Sales and Marketing

Insulin producers face fresh lawsuit in US over pricing

Phil Taylor Drug pricing, Eli Lilly, insulin, litigation, Novo Nordisk, Sanofi 0 Comment

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers

Insulin producers face fresh lawsuit in US over pricing

https://pharmaphorum.com/news/insulin-producers-face-fresh-lawsuit-in-us-over-pricing/

News/ News/ R&D

Novo Nordisk forges close ties with biotech VC Flagship

Phil Taylor drug discovery, Flagship Pioneering, Novo Nordisk, partnering, R&D 0 Comment

Danish drugmaker Novo Nordisk has traditionally generated its pipeline mainly from internal R&D, but a new alliance with

Novo Nordisk forges close ties with biotech VC Flagship

https://pharmaphorum.com/news/novo-nordisk-forges-close-ties-with-biotech-vc-flagship/

News/ News/ R&D

Novo Nordisk once-weekly insulin clears first phase 3 test

Phil Taylor Diabetes, drug delivery, insulin, insulin icodec, metabolic disease, Novo Nordisk 0 Comment

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact

Novo Nordisk once-weekly insulin clears first phase 3 test

https://pharmaphorum.com/news/novo-nordisk-once-weekly-insulin-clears-first-phase-3-test/

R&D/ Views & Analysis/ Views and analysis

Big pharma vs small diseases: Tackling rare diseases

Jonah Comstock Alexion, Novo Nordisk, pharma, rare disease 0 Comment

Rare diseases aren’t as rare as the appellation suggests. For instance, according to the US Government Accountability Office,

Big pharma vs small diseases: Tackling rare diseases

https://pharmaphorum.com/r-d/big-pharma-vs-small-diseases-tackling-rare-diseases/

News/ News/ R&D

Lilly fires a broadside at Novo Nordisk’s obesity ambitions

Phil Taylor Eli Lilly, Novo Nordisk, obesity, tirzepatide, Wegovy 0 Comment

Denmark’s Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last

Lilly fires a broadside at Novo Nordisk’s obesity ambitions

https://pharmaphorum.com/news/lilly-fires-a-broadside-at-novo-nordisks-obesity-ambitions/

R&D/ Views & Analysis/ Views and analysis

No room for commercial competition in sustainable pharma

Amanda Barrell AstraZeneca, GlaxoSmithKline, Novo Nordisk, pharma, Sustainability 0 Comment

With the healthcare sector accounting for around 4% of global emissions – about the same as a small

No room for commercial competition in sustainable pharma

https://pharmaphorum.com/r-d/commercial-competition-sustainable-pharma/

Digital/ Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

IWD: Spotlight on women in life sciences

Eloise McLennan Envair Technology, International Women's Day, Life Sciences, Merck, Novo Nordisk, STEM 0 Comment

To celebrate International Women’s Day, we speak to design engineer at Envair Technology Darina Shopova; general manager, UK

IWD: Spotlight on women in life sciences

https://pharmaphorum.com/views-and-analysis/international-womens-day-spotlight-on-women-life-sciences/

News/ News/ Sales and Marketing

Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy

Phil Taylor Novo Nordisk, obesity, Saxenda, Wegovy 0 Comment

Novo Nordisk’s rollout of obesity therapy Wegovy has been beset by production problems, but the company says these

Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy

https://pharmaphorum.com/news/novo-nordisk-eyes-obesity-sales-of-3-7bn-in-2025-thanks-to-wegovy/

Trending

Novo Nordisk

Login